User profiles for THOMAS F. E. BARTH

Prof. Dr. med. Thomas FE Barth

Pathology
Verified email at uniklinik-ulm.de
Cited by 15207

[HTML][HTML] A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling

…, W Klapper, S Wessendorf, TFE Barth… - … England Journal of …, 2006 - Mass Medical Soc
Background The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma
is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more …

[HTML][HTML] SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

…, KMJ Sparrer, P Walther, H Lickert, TFE Barth… - Nature …, 2021 - nature.com
Infection-related diabetes can arise as a result of virus-associated β-cell destruction.
Clinical data suggest that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), …

T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance

…, P Fischer-Posovszky, TFE Barth… - … , and vascular biology, 2008 - Am Heart Assoc
Background— Adipose tissue inflammation may play a critical role in the pathogenesis of
insulin resistance (IR). The present study examined the role of lymphocytes in adipose tissue …

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

H Horn, M Ziepert, C Becher, TFE Barth… - Blood, The Journal …, 2013 - ashpublications.org
MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and
confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone …

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

…, K Fiedler, HA Kestler, TFE Barth… - Blood, The Journal …, 2008 - ashpublications.org
The MYC oncogene, which is commonly mutated/amplified in tumors, represents an important
regulator of cell growth because of its ability to induce both proliferation and apoptosis. …

Interleukin 21–induced granzyme B–expressing B cells infiltrate tumors and regulate T cells

…, K Sontheimer, M Hagn, C Kaltenmeier, TFE Barth… - Cancer research, 2013 - AACR
The pathogenic impact of tumor-infiltrating B cells is unresolved at present, however, some
studies suggest that they may have immune regulatory potential. Here, we report that the …

Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network

…, S Hartmann, C Loddenkemper, TFE Barth… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose
considerable variability of individual outcome is associated with clinical characteristics (Mantle …

Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2

…, P Möller, P Lichter, TFE Barth - Blood, The Journal …, 2002 - ashpublications.org
Hodgkin- and Reed-Sternberg (HRS) cells microdissected from 41 classical Hodgkin lymphomas
(cHL) of 40 patients comprising 8 lymphocyte-rich (cHL-LR), 16 nodular sclerosis (cHL-…

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the …

…, M Frank, ML Hansmann, TFE Barth… - Blood, The Journal …, 2010 - ashpublications.org
The survival of diffuse large B-cell lymphoma patients varies considerably, reflecting the
molecular diversity of tumors. In view of the controversy whether cytologic features, …

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

…, S Brüderlein, K Dorsch, C Hasel, TFE Barth… - Blood, 2005 - ashpublications.org
Primary mediastinal B-cell lymphoma (PMBL) is a well-defined subtype of diffuse large B-cell
lymphoma. Molecular cytogenetics revealed frequent gains of 9p24. JAK2, mapping in this …